GPGilberto Aleph Prieto

Gilberto Aleph Prieto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gilberto Aleph Prieto has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Carl W. Cotman

    Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA

    12 shared publications
  • Carl W. Cotman

    Institute for Brain Aging and Dementia, University of California, Irvine, CA, USA

    5 shared publications
  • David Baglietto-Vargas

    Departamento de Biologia Celular, Genetica y Fisiologia Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina‐IBIMA Plataforma BIONAND, Facultad de Ciencias, Universidad de Malaga Malaga Spain

    5 shared publications
  • Liqi Tong

    Institute for Memory Impairments and Neurological Disorders , University of California, Irvine , Irvine , California 92697 , United States

    5 shared publications
  • E. Galarraga

    Universidad Nacional Autónoma de México [UNAM

    4 shared publications
  • A. Perez-Burgos

    Instituto de Fisiologia Celular-Neurociencias, Universidad Nacional Autonoma de Mexico (UNAM), Mexico City, Mexico

    3 shared publications

Latest Publications

  • Open Access

    TNFR2 contributes to synaptic potentiation failure in hippocampal synapses and memory loss in a familial Alzheimer’s disease mouse model

    by Jorge Luis Almazán, Eladio Cortes-Flores, Alejandro Ramírez-Olvera, Marcela Palomero-Rivero, Nohemi Camacho-Concha, Magdalena Guerra-Crespo, G. Aleph Prieto, Leonor Pérez-Martínez, Gustavo Pedraza-Alva


  • Open Access

    The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats

    by Antonio Espinosa de Los Monteros-Zúñiga, Jorge Luis Almazán, Guadalupe Martínez-Lorenzana, Mónica C. Guillen-Paredes, G. Aleph Prieto, Miguel Condés-Lara, Abimael González-Hernández

  • Open Access

    Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID

    by Elizabeth Mendoza‐Portillo, Estefania Aleman‐Navarro, G. Aleph Prieto, Yvonne Rosenstein, Jose J. Lozano‐Nuevo, Araceli Perez‐Lopez

    More than 670 million cases of coronavirus disease 2019 (COVID‐19) have been recorded worldwide in the 3 years since the start of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. About 45% of survivors of COVID‐19 develop a syndrome known as long‐term COVID, in which symptoms persist even months after the acute infection. About 76% of patients with long COVID experience neurological manifestations. Moreover, patients who have survived COVID‐19 have an increased risk of cerebral venous thrombosis. This case report describes a 41‐year‐old woman who developed neurological manifestations associated with jugular vein thrombosis 24 h after administration of the Oxford–AstraZeneca (ChAdOx1 nCoV‐19) vaccine (AstraZeneca‐Serum Institute of India). She had been infected with SARS‐CoV‐2 three months before vaccination. Although initially suspected to be a case of vaccine‐induced immune thrombotic thrombocytopenia (VITT) in view of her recent vaccination, the patient did not have any hallmarks of VITT, such as thrombocytopenia, an increased d‐dimer level, or antibodies against platelet factor‐4. Moreover, the neurological manifestations were associated with a high concentration of inflammatory cytokines, including interleukin (IL)‐6, IL‐17A, and IL‐21, and elevated neutrophil levels in cerebrospinal fluid, suggesting that inflammatory immune components had a role in the development of thrombotic events and pointing to an alternative diagnosis. In this case, the laboratory results indicated that the neurological manifestations associated with jugular vein thrombosis were not associated with VITT. Therefore, we propose that the thrombosis of the left jugular vein was a sequela of SARS‐CoV‐2 infection.


  • Open Access

    Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit

    by Arantzazu Belloso-Iguerategui, Marta Zamarbide, Leyre Merino-Galan, Tatiana Rodríguez-Chinchilla, Belén Gago, Enrique Santamaria, Joaquín Fernández-Irigoyen, Carl W Cotman, G Aleph Prieto, Ana Quiroga-Varela, et al.

    Learning and memory mainly rely on correct synaptic function in the hippocampus and other brain regions. In Parkinson’s disease, subtle cognitive deficits may even precede motor signs early in the disease. Hence, we set out to unravel the earliest hippocampal synaptic alterations associated with human α-synuclein overexpression prior to and soon after the appearance of cognitive deficits in a parkinsonism model. We bilaterally injected adeno-associated viral vectors encoding A53T-mutated human α-synuclein into the substantia nigra of rats, and evaluated them 1, 2, 4 and 16 weeks post-inoculation by immunohistochemistry and immunofluorescence to study degeneration and distribution of α-synuclein in the midbrain and hippocampus. The object location test was used to evaluate hippocampal-dependent memory. Sequential window acquisition of all theoretical mass spectrometry-based proteomics and fluorescence analysis of single-synapse long-term potentiation were used to study alterations to protein composition and plasticity in isolated hippocampal synapses. The effect of L-DOPA and pramipexole on long-term potentiation was also tested. Human α-synuclein was found within dopaminergic and glutamatergic neurons of the ventral tegmental area, and in dopaminergic, glutamatergic and GABAergic axon terminals in the hippocampus from 1 week post-inoculation, concomitant with mild dopaminergic degeneration in the ventral tegmental area. In the hippocampus, differential expression of proteins involved in synaptic vesicle cycling, neurotransmitter release and receptor trafficking, together with impaired long-term potentiation were the first events observed (1 week post-inoculation), preceding cognitive deficits (4 weeks post-inoculation). Later on, at 16 weeks post-inoculation, there was a deregulation of proteins involved in synaptic function, particularly those involved in the regulation of membrane potential, ion balance and receptor signalling. Hippocampal long-term potentiation was impaired before and soon after the onset of cognitive deficits, at 1 and 4 weeks post-inoculation, respectively. L-DOPA recovered hippocampal long-term potentiation more efficiently at 4 weeks post-inoculation than pramipexole, which partially rescued it at both time points. Overall, we found impaired synaptic plasticity and proteome dysregulation at hippocampal terminals to be the first events that contribute to the development of cognitive deficits in experimental parkinsonism. Our results not only point to dopaminergic but also to glutamatergic and GABAergic dysfunction, highlighting the relevance of the three neurotransmitter systems in the ventral tegmental area-hippocampus interaction from the earliest stages of parkinsonism. The proteins identified in the current work may constitute potential biomarkers of early synaptic damage in the hippocampus and hence, therapies targeting these could potentially restore early synaptic malfunction and consequently, cognitive deficits in Parkinson’s disease.


  • Open Access

    The role of aging and brain‐derived neurotrophic factor signaling in expression of base excision repair genes in the human brain

    by Sofie Lautrup, Camilla Myrup Holst, Anne Yde, Stine Asmussen, Vibeke Thinggaard, Knud Larsen, Lisbeth Schmidt Laursen, Mette Richner, Christian B. Vægter, G. Aleph Prieto, et al.

    DNA damage is a central contributor to the aging process. In the brain, a major threat to the DNA is the considerable amount of reactive oxygen species produced, which can inflict oxidative DNA damage. This type of damage is removed by the base excision repair (BER) pathway, an essential DNA repair mechanism, which contributes to genome stability in the brain. Despite the crucial role of the BER pathway, insights into how this pathway is affected by aging in the human brain and the underlying regulatory mechanisms are very limited. By microarray analysis of four cortical brain regions from humans aged 20–99 years (n = 57), we show that the expression of core BER genes is largely downregulated during aging across brain regions. Moreover, we find that expression of many BER genes correlates positively with the expression of the neurotrophin brain‐derived neurotrophic factor (BDNF) in the human brain. In line with this, we identify binding sites for the BDNF‐activated transcription factor, cyclic‐AMP response element‐binding protein (CREB), in the promoter of most BER genes and confirm the ability of BDNF to regulate several BER genes by BDNF treatment of mouse primary hippocampal neurons. Together, these findings uncover the transcriptional landscape of BER genes during aging of the brain and suggest BDNF as an important regulator of BER in the human brain.


  • Open Access

    Early bioenergetic and autophagy impairments at the Parkinson’s disease synapse

    by G Aleph Prieto, Carl W Cotman

    This scientific commentary refers to ‘Striatal synaptic bioenergetic and autophagic decline in premotor experimental parkinsonism’ by Merino-Galán et al. (https://doi.org/10.1093/brain/awac087).


  • Open Access

    miR‐181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer’s disease

    by Carlos J. Rodriguez‐Ortiz, Gilberto Aleph Prieto, Alessandra C. Martini, Stefania Forner, Laura Trujillo‐Estrada, Frank M. LaFerla, David Baglietto‐Vargas, Carl W. Cotman, Masashi Kitazawa

    MicroRNAs play a pivotal role in rapid, dynamic, and spatiotemporal modulation of synaptic functions. Among them, recent emerging evidence highlights that microRNA‐181a (miR‐181a) is particularly abundant in hippocampal neurons and controls the expression of key plasticity‐related proteins at synapses. We have previously demonstrated that miR‐181a was upregulated in the hippocampus of a mouse model of Alzheimer's disease (AD) and correlated with reduced levels of plasticity‐related proteins. Here, we further investigated the underlying mechanisms by which miR‐181a negatively modulated synaptic plasticity and memory. In primary hippocampal cultures, we found that an activity‐dependent upregulation of the microRNA‐regulating protein, translin, correlated with reduction of miR‐181a upon chemical long‐term potentiation (cLTP), which induced upregulation of GluA2, a predicted target for miR‐181a, and other plasticity‐related proteins. Additionally, Aβ treatment inhibited cLTP‐dependent induction of translin and subsequent reduction of miR‐181a, and cotreatment with miR‐181a antagomir effectively reversed the effects elicited by Aβ but did not rescue translin levels, suggesting that the activity‐dependent upregulation of translin was upstream of miR‐181a. In mice, a learning episode markedly decreased miR‐181a in the hippocampus and raised the protein levels of GluA2. Lastly, we observed that inhibition of miR‐181a alleviated memory deficits and increased GluA2 and GluA1 levels, without restoring translin, in the 3xTg‐AD model. Taken together, our results indicate that miR‐181a is a major negative regulator of the cellular events that underlie synaptic plasticity and memory through AMPA receptors, and importantly, Aβ disrupts this process by suppressing translin and leads to synaptic dysfunction and memory impairments in AD.


  • Open Access

    Intra- and extracellular β-amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus

    by Stefania Forner, Alessandra C. Martini, G. Aleph Prieto, Cindy T. Dang, Carlos J. Rodriguez-Ortiz, Jorge Mauricio Reyes-Ruiz, Laura Trujillo-Estrada, Celia da Cunha, Elizabeth J. Andrews, Jimmy Phan, et al.

    Alzheimer’s disease (AD), the most common age-related neurodegenerative disorder, is currently conceptualized as a disease of synaptic failure. Synaptic impairments are robust within the AD brain and better correlate with dementia severity when compared with other pathological features of the disease. Nevertheless, the series of events that promote synaptic failure still remain under debate, as potential triggers such as β-amyloid (Aβ) can vary in size, configuration and cellular location, challenging data interpretation in causation studies. Here we present data obtained using adeno-associated viral (AAV) constructs that drive the expression of oligomeric Aβ either intra or extracellularly. We observed that expression of Aβ in both cellular compartments affect learning and memory, reduce the number of synapses and the expression of synaptic-related proteins, and disrupt chemical long-term potentiation (cLTP). Together, these findings indicate that during the progression AD the early accumulation of Aβ inside neurons is sufficient to promote morphological and functional cellular toxicity, a phenomenon that can be exacerbated by the buildup of Aβ in the brain parenchyma. Moreover, our AAV constructs represent a valuable tool in the investigation of the pathological properties of Aβ oligomers both in vivo and in vitro.


  • Hippocampal gene expression patterns linked to late-life physical activity oppose age and AD-related transcriptional decline

    by Nicole C. Berchtold, G. Aleph Prieto, Michael Phelan, Daniel L. Gillen, Pierre Baldi, David A. Bennett, Aron S. Buchman, Carl W. Cotman


  • Open Access

    Tau underlies synaptic and cognitive deficits for type 1, but not type 2 diabetes mouse models

    by Laura Trujillo‐Estrada, Cassidy Nguyen, Celia da Cunha, Lena Cai, Stefania Forner, Alessandra C. Martini, Rahasson R. Ager, Gilberto Aleph Prieto, Carl W. Cotman, David Baglietto‐Vargas, et al.

    Diabetes mellitus (DM) is one of the most devastating diseases that currently affects the aging population. Recent evidence indicates that DM is a risk factor for many brain disorders, due to its direct effects on cognition. New findings have shown that the microtubule‐associated protein tau is pathologically processed in DM; however, it remains unknown whether pathological tau modifications play a central role in the cognitive deficits associated with DM. To address this question, we used a gain‐of‐function and loss‐of‐function approach to modulate tau levels in type 1 diabetes (T1DM) and type 2 diabetes (T2DM) mouse models. Our study demonstrates that tau differentially contributes to cognitive and synaptic deficits induced by DM. On one hand, overexpressing wild‐type human tau further exacerbates cognitive and synaptic impairments induced by T1DM, as human tau mice treated under T1DM conditions show robust deficits in learning and memory processes. On the other hand, neither a reduction nor increase in tau levels affects cognition in T2DM mice. Together, these results shine new light onto the different molecular mechanisms that underlie the cognitive and synaptic impairments associated with T1DM and T2DM.